Insmed Incorporated is a global biopharmaceutical company dedicated to developing therapies for patients with serious and rare diseases. Headquartered in Bridgewater, New Jersey, Insmed operates with a patient-first approach, emphasizing core values such as collaboration, accountability, passion, respect, and integrity. The company has established a significant global presence, with offices and research facilities across the United States, Europe, and Japan, and employs over 1,000 individuals committed to transforming patient lives.
Founded in 1999, Insmed has evolved through strategic growth and innovation. The company has expanded its research capabilities by establishing facilities in locations such as Cambridge, UK, and San Diego, California. The Cambridge team focuses on synthetic rescue approaches to identify novel drug targets for genetic diseases, while the San Diego team specializes in gene therapy development. These expansions underscore Insmed's dedication to pioneering scientific research and developing life-transforming therapies.
The company's product portfolio includes ARIKAYCE® (amikacin liposome inhalation suspension), the first and only FDA-approved treatment for Mycobacterium avium complex (MAC) lung disease in adult patients with limited or no alternative treatment options. Insmed's pipeline features several promising candidates, such as brensocatib, an oral DPP1 inhibitor being investigated for non-cystic fibrosis bronchiectasis, and TPIP (treprostinil palmitil inhalation powder), which is in development for pulmonary hypertension. These programs reflect Insmed's commitment to addressing unmet medical needs in the realm of rare and serious diseases.
Insmed's culture and workplace environment have garnered industry recognition. The company has been certified as a Great Place to Work® in the U.S. and ranked No. 1 on Science magazine’s Top Biopharma Employers List for multiple consecutive years. These accolades reflect Insmed's commitment to fostering an inclusive and dynamic work environment, which is integral to its mission of delivering innovative treatments to patients worldwide.